Biohaven starts first-in-human Phase 1 trial of oral PKM2 modulator BHV-8100

Biohaven

Biohaven

BHVN

0.00
  • Biohaven began first-in-human dosing of BHV-8100, an oral, brain-penetrant PKM2 modulator, in a Phase 1 study in healthy participants.
  • Early results have already been presented from the ongoing trial, showing tolerability consistent with continued dose escalation and a profile supporting once-daily dosing.
  • Separate human brain model work also already reported showed signs of improved brain energy use, with a stronger effect in Alzheimer’s donor tissue.
  • The program positions BHV-8100 as a potential platform asset across neurodegenerative, neuroinflammatory, retinal, and selected systemic inflammatory diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE72133) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.